Indianapolis, IN, United States of America

Miles Goodman Siegel

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 6 EPO patents. Top assignee: Eli Lilly and Company. Active years: 1999-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miles Goodman Siegel. Retrieved from https://idiyas.com/inventor/miles-goodman-siegel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 45.5

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 61(Granted Patents)

Company Filing History:

11 out of 4,514

Eli Lilly and Company

patents

Years Active: 1999-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10336726 - 3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists (2019-07-02),

2. 9708297 - CGRP receptor antagonists (2017-07-18),

3. 9637495 - CGRP receptor antagonists (2017-05-02),

4. 8101638 - 6-substituted nicotinamide derivatives as opioid receptor antagonists (2012-01-24),

5. 7902372 - Opioid receptor antagonists (2011-03-08),

6. 7399774 - 6-substituted nicotinamide derivatives as opioid receptor antagonists (2008-07-15),

7. 7378448 - Diphenylether amide derivatives as opioid receptor antagonists (2008-05-27),

8. 6730792 - &bgr;3 adrenergic agonists (2004-05-04),

9. 6126932 - Polymer bound carbodiimide coupling reagent (2000-10-03),

10. 5998630 - Carbodiimide coupling reagent (1999-12-07),

11. 5942536 - N-�2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT.sub.1F (1999-08-24),

Title: Miles Goodman Siegel: Innovator in Pharmaceutical Chemistry

Introduction

Miles Goodman Siegel is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as CGRP receptor antagonists. With a total of 11 patents to his name, Siegel's work has had a substantial impact on medical research and drug development.

Latest Patents

Among his latest patents, Siegel has developed compounds such as 3-methyl-pyrrolidine-2,5-dione derivatives, which are useful as CGRP receptor antagonists. The present invention provides a compound of Formula II or a pharmaceutically acceptable salt or hydrate thereof, which is beneficial in treating various medical conditions. Additionally, he has patented CGRP receptor antagonists, further showcasing his innovative approach to pharmaceutical solutions.

Career Highlights

Miles Goodman Siegel is currently associated with Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development in the field of pharmaceuticals.

Collaborations

Some of his notable coworkers include Russell Dean Stucky and James E Fritz. Their collaborative efforts have led to advancements in drug development and have strengthened the research initiatives at Eli Lilly.

Conclusion

Miles Goodman Siegel's contributions to pharmaceutical chemistry and his innovative patents have positioned him as a key figure in the industry. His work continues to influence the development of new therapeutic options, making a lasting impact on healthcare.

Profile summary based on public USPTO records.